Trials / Completed
CompletedNCT06462118
A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects
A Phase 1, Open-Label, Randomized, Single Dose Study to Evaluate the Effect of Injection Site on the Pharmacokinetics of Astegolimab in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 78 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main objective is to study how astegolimab may behave in the body when injected subcutaneously into the abdomen, thigh, or upper arm in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Astegolimab | Participants will receive one SC dose of astegolimab in the abdomen, upper arm, or thigh. |
Timeline
- Start date
- 2024-06-17
- Primary completion
- 2024-10-22
- Completion
- 2024-10-22
- First posted
- 2024-06-17
- Last updated
- 2025-01-30
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06462118. Inclusion in this directory is not an endorsement.